ibusinesslines.com
ibusinesslines.com July 16, 2018


HC Wainwright Downgrades Zynerba Pharmaceuticals to Hold

09 August 2017, 12:32 | Melissa Porter

HC Wainwright Downgrades Zynerba Pharmaceuticals to Hold

Zynerba's Clinical Trial Miss Devastates Stock Price

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs. (ZYNE) stock price comparison to its moving averages, shares of company spotted the move of -15.58% isolated from the 50-day moving average and derived -13.35% away from 20-day moving average in the most recent session. Piper Jaffray Companies cut shares of Zynerba Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $42.00 to $7.00 in a report on Monday. On average, analysts expect that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Tuesday, August 1st.

Zynerba Pharma CS (NASDAQ:ZYNE) shares traded on -55.71% down secure line and closed at $6.67. Finally, HC Wainwright set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 1st. (NASDAQ:ZYNE) from a sell rating to a hold rating in a research report sent to investors on Wednesday, July 12th. "(NASDAQ:ZYNE) Given a $8.00 Price Target at Oppenheimer Holdings, Inc." was originally published by StockNewsTimes and is owned by of StockNewsTimes. Zynerba Pharmaceuticals, Inc. The firm's market capitalization is $88.42 million. Finally, Jefferies Group LLC restated a "buy" rating and issued a $32.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Thursday, May 25th. 1,077,420 shares of the stock were exchanged. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) notched a 12-month high of $32.25 while $42.00 target is by far the most aggressive out of analysts who are now evaluating ZYNE, $9.75 higher than the next highest 52-week price estimate. Accern also assigned media headlines about the company an impact score of 45.2667347720794 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Its up 0.02% from 2.21M shares, reported previously. The stock declined 0.82% or $0.07 reaching $8.45 on the news. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Analysts forecast EPS of $-0.60, up exactly $0.10 or 14.29 % from 2014's $-0.7 EPS. Canaccord Genuity initiated it with "Buy" rating and $35 target in Monday, September 14 report. The stock has slashed -19.16% to a low over the previous 12 months and showed declining move -74.30% to a high over the same period.

P/E of the company is not reported. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock. Essex Investment Mgmt Communication Limited Liability Company holds 0.16% or 106,490 shares.


Among 6 analysts covering Zynerba Pharme...

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base.

In a report released yesterday, Cantor Fitzgerald also downgraded the stock to Hold with a $4 price target. The stock has "Buy" rating by Oppenheimer on Monday, June 26. The firm earned "Hold" rating on Monday, August 7 by Maxim Group. The company was initiated on Thursday, March 17 by Roth Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.



Other News

Trending Now

Pre-Orders for Ni No Kuni II: Revenant Kingdom Now Available
However, Ni No Kuni II has a season pass and Bandai Namco has glimpsed the Ni No Kuni II Season Pass as part of special editions. Ni no Kuni II was originally announced in 2015 and was recently delayed to early next year.

Manchester United revive interest in Tottenham left-back Danny Rose
United have shown interest in signing him and have been playing Daley Blind and Matteo Darmian in his position in pre-season.

Tottenham handed huge blow ahead of season opener against Newcastle
The 26-year-old England worldwide was later seen holding crutches while wearing a protective boot. Kieran Trippier of Spurs goes off injured during the pre-season match against Juventus .

Tillerson urges Asian nations to pressure North Korea
Malaysia and Singapore also are among a few nations in the world to offer visa-free travel to North Korea. North Korea maintains eight embassies in Southeast Asia, including in Thailand, Malaysia and Indonesia.

Cynthia Nixon knocks Cuomo but won't commit to challenge him
The problem is partly because of property taxes: Wealthy districts have more tax dollars to use for schools than poorer districts. Nixon is one of three Democrats, but certainly the best known, who have been mentioned as potential primary challengers to Cuomo.

$350M Bel Air estate is the nation's most expensive listing
Outdoor features include meticulously manicured gardens, fountains, a tennis court, a 45-car garage and a 75-foot swimming pool. Chartwell is now on the market through Coldwell Banker Global Luxury, Hilton & Hyland and Berkshire Hathaway Home Services.

Disney to Pull Content From Netflix, Launch Streaming Service
With 438,100 avg volume, 3 days are for Axis Capital Holders Limited (NYSE:AXS)'s short sellers to cover AXS's short positions. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $13.44 billion.